Dr Reddy’s Expands Strategic Collaboration with Amgen


Dr Reddy's Laboratories has announced that it has expanded its strategic collaboration with Amgen, one of the world's leading independent biotechnology companies, to market and distribute three of Amgen's medicines in India in the therapy areas of oncology and osteoporosis. Under the terms of the collaboration, Dr Reddy's will commercialise XGEVA®(denosumab), Vectibix® (panitumumab) and Prolia® (denosumab) in India.

In 2015, Dr. Reddy's announced an initial strategic collaboration with Amgen to execute a full range of regulatory and commercial services to seek approval of and launch Amgen's Kyprolis® (carfilzomib), BLINCYTO® (blinatumomab) and RepathaTM (evolocumab) in India. The collaboration leverages the capabilities of both companies, combining Amgen's innovative therapies with Dr. Reddy's deep understanding of patient and physician needs in India.

M.V.Ramana, Executive Vice President and Head of Emerging markets and India Business, Dr Reddy's Laboratories Limited said, "We are delighted to continue our relationship with Amgen as it strengthens our constant endeavor to enhance patient's access to novel treatment options across therapy areas. These medicines provide unique treatment options to physicians to address unmet medical need in the area of oncology and osteoporosis."

Penny Wan, Amgen Vice President and General Manager, Japan Asia Pacific Region said, "We are happy to strengthen our relationship with Dr Reddy's. Amgen is committed to addressing unmet medical needs of patients in India, and we are pleased with the commitment Dr Reddy's has demonstrated toward making our medicines available in India as quickly as possible."

XGEVA is a RANK ligand (RANKL) inhibitor and is approved in India for the prevention of skeletal related events in patients with advanced malignancies involving bone.


Previous 1 3 4 5 6 7 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box


GST: Boon or Bane for Healthcare?

Send this article by email